[(18)F]-labeled 2-methoxyphenylpiperazine derivative as a potential brain positron emission tomography imaging agent

Appl Radiat Isot. 2009 Nov;67(11):2013-8. doi: 10.1016/j.apradiso.2009.07.012. Epub 2009 Aug 6.

Abstract

This study reports the synthesis and characterization of N-(3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl-4-[(18)F]fluorobenzamide ([(18)F]MPP3F). The total reaction time for [(18)F]MPP3F, including final high-performance liquid chromatography purification, was about 3h. Typical decay-corrected radiochemical yield was 18.4+/-3.1%. The radiochemical purity was >98%. Biodistribution in mice showed that [(18)F]MPP3F is a potential brain imaging agent for positron emission tomography. The brain uptake of [(18)F]MPP3F was 6.59+/-0.77% Injected Dose/g at 2 min post-injection time. A brain-to-blood ratio of 3.67 was reached at 15 min after injection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / diagnostic imaging*
  • Brain / metabolism*
  • Feasibility Studies
  • Fluorine Radioisotopes / pharmacokinetics*
  • Metabolic Clearance Rate
  • Mice
  • Organ Specificity
  • Piperazines / chemical synthesis
  • Piperazines / pharmacokinetics*
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals / chemical synthesis
  • Radiopharmaceuticals / pharmacokinetics
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Tissue Distribution

Substances

  • Fluorine Radioisotopes
  • Piperazines
  • Radiopharmaceuticals
  • phenylpiperazine